Patents Assigned to Board of Regents The University of Texas System
  • Publication number: 20240083842
    Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
    Type: Application
    Filed: November 13, 2023
    Publication date: March 14, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Daniel J. SIEGWART, Kejin ZHOU
  • Publication number: 20240084403
    Abstract: The present disclosure concerns methods and compositions related to adoptive cell therapy and its efficacy related to the gut microbiome. In specific cases, it may be determined for an individual whether or not a chimeric antigen receptor (CAR) T-cell therapy will be effective for an individual based on their gut microbiome. An individual may be provided a composition comprising one or more particular microbe compositions based on analysis of the gut microbiome of the individual and prior to administration of CAR T-cell therapy, in specific embodiments.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 14, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Neeraji Saini, Chia-Chi Chang, Robert R. Jenq, Sattva S. Neelapu
  • Publication number: 20240083951
    Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.
    Type: Application
    Filed: September 11, 2023
    Publication date: March 14, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventor: Hui-lin PAN
  • Publication number: 20240084400
    Abstract: The current disclosure describes effective therapeutic treatments and diagnostic/prognostic methods for colorectal cancer based on the expression or activity level of biomarkers. Aspects of the disclosure relate to a method for treating a subject for colorectal cancer, the method comprising treating the subject for colorectal cancer after the expression level of one or more biomarker genes from Table 1, Table 2, Table 3, Table 4, Table 5, Table S2, Table S3, Table S4, Table S5, FIG. 4A, and/or FIG. 4B has been determined in a sample from the subject.
    Type: Application
    Filed: February 22, 2022
    Publication date: March 14, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Eduardo VILAR SANCHEZ, Wenhui WU, Hiroyuki KATAYAMA, Samir HANASH, Prashant V. BOMMI
  • Publication number: 20240082342
    Abstract: Chronic tobacco smoke exposure (TSE)-induced lung injury includes increased alveolar and airway inflammation, type II alveolar epithelial cells (A2Cs) senescence and apoptosis, and mucus hypersecretion by airway epithelial cells (AECs) that can be treated by the caveolin-1 peptide CSP7 (SEQ ID NO:1). Caveolin-1 and p53 mediated induction of plasminogen activator inhibitor-1 (PAI-1) expression by interleukin 17A, TSE, pollution and other causes leads to lung injury, which can be abrogated by CSP7 treatment, which abolishes A2Cs senescence and apoptosis and AEC mucus hypersecretion. CSP7 treatment of lung tissue of patients with TSE-induced lung injury decreases A2C apoptosis and AEC mucus hypersecretion. Lung injury with A2Cs senescence and apoptosis and AEC mucus hypersecretion caused by TSE-induced PAI-1 expression in lung tissue of patients is abolished by CSP7.
    Type: Application
    Filed: October 25, 2023
    Publication date: March 14, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Sreerama SHETTY
  • Patent number: 11925579
    Abstract: The invention provides for novel glaucoma surgical devices comprising a microfluidic meshwork. The meshwork comprises interconnected, cellular-dimensioned microfluidic channels. Excess fluid in the eye can be drained and diffused through the microfluidic channels. The meshwork is porous and highly flexible, affording mechanical compliance similar to that of eye tissue. The meshwork minimizes foreign body reactions to the implant, decreasing fibrosis and capsule formation.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: March 12, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Chong Xie, Lan Luan, Ying Han
  • Patent number: 11925654
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: March 12, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Patent number: 11926824
    Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: March 12, 2024
    Assignees: Board of Regents, The University of Texas System, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Raghu Kalluri, Sónia Melo
  • Patent number: 11925642
    Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: March 12, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Greg Dussor, Jacob E. Lackovic
  • Publication number: 20240077496
    Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
    Type: Application
    Filed: June 21, 2023
    Publication date: March 7, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: David E. Gerber, Edward Wakeland, Quan Li, Saad Khan, Jason Y. Park, Xin Luo, Yang Xie
  • Patent number: 11919927
    Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.
    Type: Grant
    Filed: April 6, 2023
    Date of Patent: March 5, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jason McLellan, Ching-Lin Hsieh, Scott Rush, Nianshuang Wang
  • Patent number: 11918766
    Abstract: The disclosure provides a flexible, narrow medical device (such as a micro-catheter or a guidewire) that is controllably moved and steered through lumens of a body. The medical device may include an electrically-actuatable bendable portion at a distal end, which may be provided by a polymer electrolyte layer, electrodes distributed about the polymer electrolyte layer, and electrical conduits coupled to the electrodes, such that the polymer electrolyte layer deforms asymmetrically in response to an electrical signal through one or more conduits. The disclosure further includes a controller for moving the device into and out of bodily lumens and for applying the electrical signal for steering the device. The device further includes methods of preparing the polymer electrolyte layer in tubular shape.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: March 5, 2024
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Daniel H. Kim, Dong Suk Shin, Viljar Palmre
  • Patent number: 11919937
    Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind the T-cell leukemia/lymphoma 1 (TCL1) oncoprotein. The TCR may be utilized in various therapies, such as autologous TCL1-TCR adoptive T cell therapy, to treat a cancer, such as a B-cell malignancy or a solid tumor expressing TCL1. Methods for expanding a population of T cells that target TCL1 are also provided.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: March 5, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jinsheng Weng, Kelsey Moriarty, Sattva S. Neelapu
  • Patent number: 11918646
    Abstract: Described herein are dry immunogenic compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry composition can be readily administered without loss of activity. Also described are methods of intranasal administering dry immunogenic compositions comprising antigens and aluminum adjuvants.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: March 5, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Zhengrong Cui, Sachin G. Thakkar
  • Patent number: 11918799
    Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: March 5, 2024
    Assignees: Board of Regents, The University of Texas System, Cardio Vol, LLC
    Inventors: John Porterfield, Jonathan W. Valvano, Clay Heighten, Anil Kottam, Marc David Feldman, Aleksandra Borisovna Gruslova, Drew R. Nolen
  • Publication number: 20240068047
    Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
    Type: Application
    Filed: September 7, 2023
    Publication date: February 29, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Chandrani CHATTOPADHYAY, Janos ROSZIK
  • Publication number: 20240067713
    Abstract: Methods for treating, reducing, ameliorating or inhibiting symptoms idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia, comprising administering to a subject in need of an effective amount of a) multiple EGF-like-domains-9 (MEGF9) or a biologically active fragment thereof; b) uncoordinated receptor 5A (UNC5A) or a biologically active fragment thereof; c) dolichyl-phosphate beta-glucosyltransferase (ALG5) or a biologically active fragment thereof; d) a combination of two or three of a)-c); e) an antibody specifically binding to a); f) an antibody specifically binding to b); g) an antibody specifically binding to c); h) a combination of two or three of e)-g); or i) a combination of at least one of a)-c) and at least one of e)-g). Pharmaceutical compositions and processes for making and using the compositions are also disclosed.
    Type: Application
    Filed: October 5, 2023
    Publication date: February 29, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventor: Sreerama SHETTY
  • Patent number: 11911330
    Abstract: A robotic exoskeleton including a back portion providing at least two degrees of freedom, two shoulder portions, each shoulder portion providing at least five degrees of freedom, two elbow portions, each elbow portion providing at least one degree of freedom, and two forearm portions, each forearm portion providing at least one degree of freedom.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: February 27, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Ashish Warren Deshpande, Bongsu Kim
  • Patent number: 11912991
    Abstract: Embodiments of the disclosure concern methods and compositions related to generation and/or use of proofreading reverse transcriptases, including those that are thermophilic or hyperthermophilic. The disclosure encompasses specific recombinant polymerases and their use. In some embodiments, the polymerases are utilized for RNA sequencing in the absence of generation of a cDNA intermediate.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: February 27, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Andrew Ellington, Jared Ellefson, Jimmy Gollihar
  • Patent number: 11912762
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: February 27, 2024
    Assignee: Board of Regents of the University of Texas System
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu